AT291247B - Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen - Google Patents
Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onenInfo
- Publication number
- AT291247B AT291247B AT768868A AT768868A AT291247B AT 291247 B AT291247 B AT 291247B AT 768868 A AT768868 A AT 768868A AT 768868 A AT768868 A AT 768868A AT 291247 B AT291247 B AT 291247B
- Authority
- AT
- Austria
- Prior art keywords
- pyrazin
- imidazo
- ones
- preparation
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65904267A | 1967-08-08 | 1967-08-08 | |
| US72803368A | 1968-05-09 | 1968-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT291247B true AT291247B (de) | 1971-07-12 |
Family
ID=27097746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT768868A AT291247B (de) | 1967-08-08 | 1968-08-06 | Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3507866A (de) |
| AT (1) | AT291247B (de) |
| BE (1) | BE719154A (de) |
| CH (1) | CH516574A (de) |
| DE (1) | DE1795062A1 (de) |
| DK (1) | DK123484B (de) |
| ES (1) | ES356976A1 (de) |
| FR (2) | FR1578366A (de) |
| GB (1) | GB1193035A (de) |
| IL (1) | IL30463A0 (de) |
| NL (1) | NL6810650A (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US20050090505A1 (en) * | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) * | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US7923041B2 (en) * | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| SI2583970T1 (sl) * | 2006-08-02 | 2016-03-31 | Cytokinetics, Inc. | Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine |
| PL2069352T3 (pl) * | 2006-08-02 | 2014-03-31 | Cytokinetics Inc | Określone cząstki chemiczne, kompozycje i sposoby |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| MX337906B (es) * | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| EP2139478A4 (de) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | Bestimmte chemische entitäten, zusammensetzungen und verfahren |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| SG10201500511TA (en) | 2009-10-26 | 2015-03-30 | Signal Pharm Llc | Methods Of Synthesis And Purification Of Heteroaryl Compounds |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| BR112014000742A2 (pt) | 2011-07-13 | 2016-08-23 | Andrew A Wolff | terapia de combinação de als |
| PH12014500869A1 (en) | 2011-10-19 | 2014-06-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
| KR102040997B1 (ko) | 2011-12-02 | 2019-11-27 | 시그날 파마소티칼 엘엘씨 | 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법 |
| EP2817029B1 (de) | 2012-02-24 | 2019-07-10 | Signal Pharmaceuticals, LLC | Verfahren zur behandlung von nicht kleinzelligen lungenkrebs mit tor kinasehemmerkombinationstherapie |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| SG10201708931XA (en) | 2012-12-17 | 2017-12-28 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| RU2018138195A (ru) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| PE20151995A1 (es) | 2013-01-16 | 2016-01-13 | Signal Pharm Llc | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| US9630966B2 (en) | 2013-04-17 | 2017-04-25 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CA2909579A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| CN105377299B (zh) | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| ES2823756T3 (es) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
-
1968
- 1968-05-09 US US728033A patent/US3507866A/en not_active Expired - Lifetime
- 1968-07-26 NL NL6810650A patent/NL6810650A/xx unknown
- 1968-07-29 IL IL30463A patent/IL30463A0/xx unknown
- 1968-08-05 DE DE19681795062 patent/DE1795062A1/de active Pending
- 1968-08-05 GB GB37296/68A patent/GB1193035A/en not_active Expired
- 1968-08-06 AT AT768868A patent/AT291247B/de not_active IP Right Cessation
- 1968-08-06 ES ES356976A patent/ES356976A1/es not_active Expired
- 1968-08-07 BE BE719154D patent/BE719154A/xx unknown
- 1968-08-07 CH CH1183068A patent/CH516574A/de not_active IP Right Cessation
- 1968-08-07 DK DK379768AA patent/DK123484B/da unknown
- 1968-08-08 FR FR1578366D patent/FR1578366A/fr not_active Expired
- 1968-11-08 FR FR173159A patent/FR8409M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK123484B (da) | 1972-06-26 |
| US3507866A (en) | 1970-04-21 |
| ES356976A1 (es) | 1970-10-16 |
| NL6810650A (de) | 1969-02-11 |
| GB1193035A (en) | 1970-05-28 |
| BE719154A (de) | 1969-02-07 |
| IL30463A0 (en) | 1968-09-26 |
| CH516574A (de) | 1971-12-15 |
| FR1578366A (de) | 1969-08-14 |
| FR8409M (de) | 1971-03-31 |
| DE1795062A1 (de) | 1972-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT291247B (de) | Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen | |
| CH505118A (de) | Verfahren zur Herstellung von 1,2,4-Triazin-5-onen | |
| AT275521B (de) | Verfahren zur Herstellung von neuen 1,4-Dihydropyridinderivaten | |
| CH481110A (de) | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen | |
| CH502364A (de) | Verfahren zur Herstellung von neuen 1,2,4-Oxadiazolen | |
| AT281836B (de) | Verfahren zur Herstellung von neuen 2-Methyl-3-carbonsäureamido-chinoxalin-di-N-oxiden-(1,4) | |
| AT277221B (de) | Verfahren zur Herstellung von neuen 5-Nitro-2-furyl-2-isoxazolin-derivaten | |
| CH496022A (de) | Verfahren zur Herstellung von neuen N,N'-Diglycidyl-Verbindungen | |
| AT291250B (de) | Verfahren zur Herstellung von neuen 5-NR<1>R<2> -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen | |
| AT277985B (de) | Verfahren zur Herstellung von neuen Nitro-furan-, -thiophen- oder -pyrrol-derivaten | |
| CH498132A (de) | Verfahren zur Herstellung neuer Pyrido (1,2-a)-s-triazindione | |
| AT284128B (de) | Verfahren zur Herstellung von neuen 2-Halogenmethyl-3-carbansäureamido-chinoxalin-di-N-oxiden-(1,4) | |
| AT280271B (de) | Verfahren zur Herstellung von neuen Cumarinyl-v-triazoloxydderivaten | |
| AT281838B (de) | Verfahren zur Herstellung von neuen 2-Isothiuronium-methyl-3-carbonsäureamido-chinoxalin-di-N-oxid-(1,4)-halogeniden | |
| AT299172B (de) | Verfahren zur Herstellung von neuen Naphthylisopropyl-Derivaten | |
| CH489525A (de) | Verfahren zur Herstellung von 1,8-Naphthyridinderivaten | |
| AT283356B (de) | Verfahren zur Herstellung von neuen 1,2,4-Oxdiazolidin-Derivaten | |
| CH508645A (de) | Verfahren zur Herstellung von neuen 5-substituierten y-Carbolinderivaten | |
| CH453370A (de) | Verfahren zur Herstellung von neuen 5,6-Dihydro-6-oxo-pyrido (2,3-b)(1,4)benzoxazepinen | |
| AT290026B (de) | Verfahren zur Herstellung von neuen 22-Amino-23,24-bisnorcholanderivaten | |
| AT293634B (de) | Verfahren zur Herstellung von neuen 17α-Acyloxy-11β-methyl-19-norpregn-4-en-3,20-dionen | |
| CH522619A (de) | Verfahren zur Herstellung von neuen Derivaten von 2a,3a-Epithioandrostanen | |
| AT291967B (de) | Verfahren zur Herstellung von neuen N-Phenyl-N-2-fluor-1,1,2,2,-tetrachloräthylsulfenyl-sulfamiden | |
| CH469729A (de) | Verfahren zur Herstellung von neuen 4,9-Dihydrothieno-(2,3-b)-benzo-(e)-thiepinderivaten | |
| AT281020B (de) | Verfahren zur Herstellung von neuen 3-Imino-1,2-benzisothiazolinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ELJ | Ceased due to non-payment of the annual fee |